Cell子刊：脂肪肝的菌群疗法——机遇和挑战 （综述） | 热心肠日报
非酒精性脂肪肝疾病基于肠道微生物组的个性化医学的最新概念、机遇和挑战
10.1016/j.cmet.2020.11.010
12-08, Review
Abstract & Authors:展开
Abstract:收起
Nonalcoholic fatty liver disease (NALFD) is now a leading cause of chronic liver disease worldwide, in part, as a consequence of rapidly rising levels of obesity and metabolic syndrome and is a major risk factor for cirrhosis, hepatocellular carcinoma, and liver-related mortality. From NAFLD stems a myriad of clinical challenges related to both diagnosis and management. A growing body of evidence suggests an intricate linkage between the gut microbiome and the pathogenesis of NAFLD. We highlight how our current knowledge of the gut-liver axis in NAFLD may be leveraged to develop gut microbiome-based personalized approaches for disease management, including its use as a non-invasive biomarker for diagnosis and staging, as a target for therapeutic modulation, and as a marker of drug response. We will also discuss current limitations of these microbiome-based approaches. Ultimately, a better understanding of microbiota-host interactions in NAFLD will inform the development of novel preventative strategies and precise therapeutic targets.
First Authors:
SR Sharpton
Correspondence Authors:
R Loomba
All Authors:
SR Sharpton,B Schnabl,R Knight,R Loomba